Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "gilead"


25 mentions found


"We are the Underground Railroad of 'Gattaca' babies and people who want to do genetic stuff with their kids," Malcolm told me. Ellison, meanwhile, who has two children in their 30s, has reportedly resumed having kids — with his 31-year-old girlfriend. "The person of this subculture really sees the pathway to immortality as being through having children," Simone said. The person of this subculture really sees the pathway to immortality as being through having children. Before she met Malcolm, Simone was convinced she wanted to live her life single and child-free.
The review, conducted by the National Institute for Health and Care Excellence (NICE) and published on Wednesday, is its first involving COVID-19 treatments as the pandemic enters a new phase. The recommendations are a draft, NICE said, and until final guidance is published, access to COVID-19 medicines will continue as is. NICE acknowledged that there is evidence that Merck's molnupiravir and Gilead Sciences Inc's (GILD.O) hospital-administered antiviral remdesivir are effective at treating COVID-19. It also recommended against three other COVID treatments, including GSK (GSK.L) and partner Vir Biotechnology's (VIR.O) sotrovimab, an antibody therapy that the World Health Organization recommended against in September. One expert said that some of the COVID treatments NICE recommended against are an important part of the British government's current strategy.
Cantor Fitzgerald analysts named six big events to mark on your calendar. While the majority of the expected events are set to come from smaller biotech companies, bigger companies — like Roche, Gilead, and Alnylam — have their own events coming through the pipeline. Here are the six major events from big biotech companies that could send stocks soaring:1. Cantor Fitzgerald analysts give Gilead's stock a neutral rating and they have an overweight rating on Arcus. Lenacapavir "could become a much bigger piece of the HIV growth narrative over the next few years," according to Cantor Fitzgerald analysts.
Editor’s Note: The following contains spoilers about “The Handmaid’s Tale” Season 5 finale, “Safe.”CNN —“The Handmaid’s Tale” certainly doesn’t suffer from a lack of media exposure or cultural capital, with recent turns in the battle over abortion rights generating regular references in progressive circles to the threat of America becoming Gilead, the repressive patriarchal society featured in Margaret Atwood’s novel. Appropriately, the finale wrapped up aboard a train, because while the show didn’t quite go off the rails, it at times seemed to come perilously close. Ultimately, the last episode, “Safe,” reunited the two characters whose bond — forged in pain and hatred — completely defined Season 5. A gruesome attack on June and botched military operation to recover the lost girls, underscored that this is indeed a war, with casualties as the inevitable byproduct. “And then it was too f**kin’ late.”In that moment, anyway, “The Handmaid’s Tale” offered a riveting reminder of what made the series such an Emmy-winning sensation when it began.
DETROIT/WASHINGTON, Nov 7 (Reuters) - Stellantis (STLA.MI) said on Monday it is pausing all paid advertising posts on Twitter as it waits to see what the platform will look like under the leadership of its new owner Elon Musk. “We're pausing paid advertising posts until we have a clearer understanding of the future of the platform under its new leadership," the automaker said of Twitter in a statement to Reuters. Musk has said Twitter has suffered a "massive" revenue drop since he took over 10 days ago. Stellantis joins a number of major companies that have halted advertising on Twitter, including United Airlines (UAL.O), General Mills Inc (GIS.N) luxury automaker Audi of America and General Motors Co (GM.N). Gilead Sciences Inc (GILD.O) said earlier on Monday the company and its unit Kite were in the "process of pausing advertising" on Twitter.
WASHINGTON, Nov 7 (Reuters) - The U.S. Supreme Court on Monday rebuffed a bid by Bristol Myers Squibb Co's Juno Therapeutics Inc to reinstate a $1.2 billion award it won in its patent fight with Gilead Sciences Inc (GILD.O) subsidiary Kite Pharma Inc over a lymphoma drug. The justices turned away Juno's appeal of a lower court's ruling throwing out the award in the litigation over Kite's biologic drug Yescarta, in a case that could have repercussions for the cutting-edge biologic drug industry. Juno and Sloan Kettering Institute for Cancer Research sued Kite in 2017 in federal court in Los Angeles, accusing it of copying technology that the institute licenses to Juno. Juno and Sloan Kettering have told the Supreme Court that the Federal Circuit's decision to invalidate the patent and other rulings against biologic patents have been "devastating for innovation." On Nov. 4, the Supreme Court took up another patent case involving biologic drugs, agreeing to hear Amgen's bid to revive patents on its cholesterol drug Repatha.
Gilead, Kite in process of pausing Twitter advertising
  + stars: | 2022-11-07 | by ( ) www.reuters.com   time to read: +1 min
Nov 7 (Reuters) - Gilead Sciences Inc (GILD.O) said on Monday the company and its unit Kite were in the "process of pausing advertising" on Twitter, after Elon Musk completed his takeover of the social media company. In a statement to Reuters, Gilead said it was monitoring its advertising spend and waiting to better understand how community standards and content moderation will be handled on Twitter now. Gilead joins a growing list of U.S. companies, including General Motors (GM.N) and General Mills (GIS.N), who have either paused or are in the process of re-evaluating advertising on the social media platform. Last week, the Wall Street Journal reported Oreo maker Mondelez International Inc (MDLZ.O) and U.S. drugmaker Pfizer Inc (PFE.N) had also temporarily halted advertising with Twitter. Reporting by Bhanvi Satija and Raghav Mahobe in Bengaluru; Editing by Krishna Chandra EluriOur Standards: The Thomson Reuters Trust Principles.
Apple – Shares of Apple jumped 8% after the technology giant beat both top and bottom line estimates when it reported earnings results for its latest quarter. Amazon – Shares of Amazon slipped 9% Friday after the retailer on Thursday reported quarterly revenue that fell short of Wall Street's expectations. T-Mobile – T-Mobile stock jumped 6% after the telecom company reported the largest jump in subscriber numbers since 2020, when it merged with Sprint. Pinterest – Pinterest rose 8% after the social media company beat earnings expectations and reported more monthly users than analysts forecast. The medical equipment company reported quarterly results on Thursday, posting revenue that slightly beat expectations, according to consensus estimates on StreetAccount.
Goldman Sachs reiterates Amazon as buy Goldman said it's standing by shares of Amazon after its "mixed" earnings report on Thursday. Morgan Stanley reiterates Apple as overweight Morgan Stanley says Apple is still "best of breed" after its earnings report on Thursday. Morgan Stanley reiterates Ford as overweight Morgan Stanley says it likes Ford more as a "restructuring play" than as a way to play the electric vehicle sector. Morgan Stanley reiterates Costco as overweight Morgan Stanley says the stock is defensive and in "rare air." Morgan Stanley reiterates McDonald's as overweight Morgan Stanley said the fast food giant is a must-own "in these times" after its earnings report on Thursday.
Piper Sandler and Truist upgraded the stock to overweight and buy ratings, respectively, after the company topped earnings expectations for the recent quarter and shared upbeat guidance. Both firms said they anticipate solid growth from Gilead's oncology and HIV franchises going forward, saying now is the time to get in on the stock. Kim upped the firm's price target on the stock to $96 from $79 a share, suggesting 37% upside from Thursday's close. Truist's Robyn Karnauskas highlighted the potential of Gilead's cancer drugs and therapies in a note to clients, hiking the firm's price target on the stock to $91 per share. Gilead's stock jumped nearly 5% in Friday's premarket.
Morning Bid: Meta averse, ECB decides and CS slides
  + stars: | 2022-10-27 | by ( ) www.reuters.com   time to read: +4 min
A look at the day ahead in U.S. and global markets from Mike Dolan. Meta added a deep pothole to an already bumpy U.S. earnings season - another obstacle to a market pumped-up by bets of some central bank relief on the horizon as G7 economies slow. read moreWith Apple (AAPL.O) and Amazon reporting later on Thursday, sentiment toward tech giants remains on edge. But after two-week, trough-to-peak bounce of almost 10%, global stock indices (.MIWD00000PUS) struggled to make much headway for the second session on Thursday. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.
Apple — Apple share fell as much as about 4% following its quarterly financial report, which included weaker-than-expected iPhone revenue. Apple still beat Wall Street estimates for its earnings and revenue, however, and the shares pared their losses. Pinterest — The social media platform's shares climbed 15% postmarket after it third-quarter earnings and revenue both topped estimates. Gilead Sciences — The pharma company added about 4% after third quarter earnings beat analyst estimates, according to FactSet. Earnings and revenue for the third quarter beat analysts' estimates, according to FactSet.
Troubling recent reports reveal the emergence of new omicron subvariants that not only evade AstraZeneca’s Evusheld, the antibody drug authorized to prevent Covid infection, but also the sole antibody drug that has retained effectiveness as treatment for Covid, Eli Lilly’s bebtelovimab. Doctors have cautioned that should Laura get Covid, this could aggravate her autoimmune disease and lead to catastrophic kidney damage. Evusheld is a long-acting antibody injection given every six months that studies have suggested provides a robust buffer to the immunosuppressed. For now, immunocompromised people are anxiously watching the pandemic forecast to see if the subvariants that research indicates evade monoclonal antibodies will become predominant. “If fewer people are prescribed Evusheld,” she said, “there’s less incentive for drug companies to start developing newer therapeutics.
Stocks rallied this week as earnings season ramped up and is so far off to a better-than-expected start. With 20% of the S & P 500 having reported financials so far, sales results have thus far been 1.4% above expectations while earnings results are 5.4% above expectations, in aggregate. That inverse correlation between bond yields and stocks was powerful enough to trump positive earnings reports. Looking back On the earnings front, we got results from Johnson & Johnson (JNJ), Procter & Gamble (PG), and Danaher (DHR). As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.
The three major averages closed higher Friday, with the S & P 500 adding 2.37% to close at 3,752.75. Stovall said the S & P 500 had six positive moves of 1% or more in the last 17 trading days, as of Friday. Earnings, earnings, earnings About 150 S & P 500 companies report earnings in the coming week. Technically speaking Scott Redler, partner with T3Live.com, said he is watching a formation in the S & P 500 that could be positive. His first target for the S & P 500 is 3,800.
There are currently no proven vaccines or treatments for the Sudan species of Ebola, one of four known Ebola viruses to cause hemorrhagic fever in humans. The outbreak confirmed by the Ugandan health ministry on Sept. 20 is the largest of the Sudan species since 2000. "If healthcare workers start to fall ill and die, it's going to negatively impact the response," said Montgomery, who had just returned from a trip to Uganda. For instance, healthcare workers may be reluctant to assist in the response, he said in a phone interview. A large outbreak of the Zaire species of Ebola in West Africa from 2014-2016 led to effective vaccines and treatment, but there are no proven treatments or vaccines for the Sudan species.
Index Ventures VCs Nina Achadjian and Paris Heymann are betting on vertical software in the downturn. Here's how founders of vertical-software companies can pitch them. Vertical software, or software tailored to specific industries, is poised to do well amid the current economic downturn, two VCs at Index Ventures said. When considering vertical-software companies to invest in, the most important thing they look for is the right kind of founding team. For vertical-software companies, it's important that the founders are familiar with the industry they're trying to sell to, they said.
Drawing from the dot-com crash, he believes the current bear market still has 15%-20% more downside. Abate also shared the biggest mistake investors could make once the Fed begins to ease once more. Today's bear market mirrors the dot-com crashPart of Abate's investment process involves drawing parallels between the current market and historical recessions. "I still think that we are in the midst of a bear market. Similarly, both bear markets were also kicked off by an "excessive period of poor allocation of investment capital," Abate said.
James Abate's fund has beaten 99% of its peers this year and over one, three, and five years. Here are his 9 standout stock picks which he says have enough pricing power to beat the bear market. He compared this dogmatic style of investing — purposely ignoring opportunities in the market — to horses running around a track with blinders on. Within energy, Abate specifically likes more gas-related names versus oil-related ones, with two standouts including Exxon Mobil (XOM) and EQT (EQT). Below is the full list of Abate's nine standout stocks along with the ticker, market capitalization, and sector for each.
"That said, the biggest drugs usually feature one, or best case two, of these attributes." Seven drugs on Meacham's list are already in the market, and have already hit the $10 billion or more benchmark. That means some of these drugs may be already hitting the end of their peak sales period. Meacham has previously said that one of the drugs in this bucket, Eli Lilly's tirzepatide, could be the first $100 billion drug . But many investors are hopeful about its potential as an obesity treatment .
Sept 28 (Reuters) - A federal judge in New York has frozen the assets of dozens of people and entities accused of operating a massive nationwide scheme to distribute counterfeit bottles of Gilead Sciences Inc (GILD.O) HIV drugs, including two alleged "kingpins." HIV drugs accounted for $7.6 billion of Gilead's $12.6 billion revenue in the first half of the year. read moreThe newly added defendants include alleged "kingpins" Lazaro Roberto Hernandez, who was arrested on drug counterfeiting and money laundering charges in June as part of a related federal investigation and remains under house arrest, and Armando Herrera, who lives in Florida. The Foster City, California-based company first announced it was pursuing counterfeiters in August 2021, shortly after filing its lawsuit. read moreIn addition to the alleged kingpins, the case now includes alleged mid-level leaders and a complex web of shell companies, distributors and pharmacies.
Investors have looked to health care as a port in the storm during the stock market's volatility over the last year. In health care, "you still have companies that are throwing off good yield, so you get stability and good dividend yields." Biotech and pharmaceuticals industries have an average dividend yield of 2.6%, ranking just behind the consumer staples, utilities, and energy sectors. Just two stocks made the grade: drug maker AbbVie and pharmacy and health services giant CVS Health. The company, which includes pharmacy benefits as well the Aetna health insurance division, has a dividend yield of 2.1%.
Quality stocks are those that generate robust and stable profits, and have high returns on equity. In addition to having robust profit margins, Stimpson also likes firms that show strong earnings growth. 8 stocks Stimpson is betting onTwo sectors in the market with a growth tilt are technology and healthcare. He also likes semiconductor firms because he thinks they're oversold and undervalued. Four semiconductor firms he likes include: Cirrus Logic (CRUS), Ambarella (AMBA), KLA-Tencor (KLA), and Kulicke & Soffa Industries (KLIC).
A mosaic of human cells inside Vertex Pharmaceuticals' cell and gene-therapy laboratory. The four-story, 267,000-square-foot space is home to Vertex's cell and gene-therapy unit, with about 375 people now residing in the modern-industrial building. That has led to going after unrelated diseases like sickle cell, diabetes, muscular dystrophy, kidney disease, and pain. For instance, Vertex's approach to sickle cell is led by its CRISPR gene-editing program. Vertex PharmaceuticalsThe next test of Vertex's strategy will be an experimental treatment called exa-cel, its CRISPR gene-editing program for sickle cell.
A Chronic Disease Still Waiting for a Drug
  + stars: | 2022-09-20 | by ( David Wainer | ) www.wsj.com   time to read: +1 min
Drug companies have developed treatments for some of the rarest diseases afflicting a tiny percentage of the population, yet they have failed repeatedly to get a drug on the market for a chronic and increasingly common one. As biotech companies take new shots on goal for the liver disease known as NASH, or nonalcoholic steatohepatitis, investors are understandably reluctant after being burned repeatedly. Take Intercept Pharmaceuticals which at the height of the Wall Street excitement over NASH treatments fetched as much as $462 a share. The stock has since plunged, trading now at just over $17, erasing $6 billion in market value. The biotech’s drug for NASH was rejected by the U.S. Food and Drug Administration in 2020 because of safety concerns, but Intercept is trying again.
Total: 25